New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.
Sabin is happy to announce the arrival of our 2012 Annual Report, featuring highlights from our three programs – Vaccine Advocacy and Education, The Sabin Product Development Partnership, and the Global Network for Neglected Tropical Diseases.

Human hookworm, schistosomiasis, Chagas disease and leishmaniasis are some of the most devastating diseases in poverty with no licensed vaccine available.

Reposted with permission from the TAMEST blog, which is run by the Academy of Medicine, Engineering & Science of Texas. 

Addressing the Neglected Diseases Treatment Gap: Testimony from Dr. Peter Hotez for the House Committee on Foreign Affairs

Dr. Peter Hotez testified on Neglected Tropical Diseases before the House Sub Committee on Africa, Global Health, Global Human Rights, and international organizations on June 27th. 

Highlight from the testimony:

Pages